The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Think CW25 put it well at the start of this thread:
“The team at SNG have moved mountains to get a p2 and worldwide P3 completed in 2 years. In normal times that would take over 5 years. We are not Pfizer or AZ so we were up against all the big boys trying to fill our trial, when they were also trialling their drugs. But they have done it and that’s no mean feat. We are potentially just days away from our P3 readout and a potential breakthrough anti viral drug that could be in every hospital around the world within the next year. Yes America will be first but the new recruits for Europe today shows that we are not ignoring closer to home too. There’s a big market out there and the team that RM is building will be capable of selling to every government and healthcare system around the world. Not forgetting the potential for stockpiling for future pandemics.
Ignore the white noise of some posters and prepare yourself for a once in a lifetime opportunity and life changing returns if all comes to fruition.
Good luck and don’t let them take your shares off you too cheap!”
And the first one is in the Lancet ;)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00063-X/fulltext
And another one, though beta-1b
Interferon beta-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease
https://onlinelibrary.wiley.com/doi/10.1002/jmv.26976
Endogenous interferon-beta but not interferon-alpha or interferon-lambda levels in nasal mucosa predict clinical outcome in critical COVID-19 patients independent of viral load
https://www.medrxiv.org/content/10.1101/2021.03.23.21253748v1.full-text
Actually, orgaston may be a genius.
Every time he does one of his £3-5 per share posts a whole lot of us, me included, pile in to say that he’s wrong, deluded etc. What better way to ramp a stock than have everyone else do it for you?!
Or for that matter up to date?!
CR1909, the UBS AG holding was tweeted at https://twitter.com/AIMdective/status/1373204616989540353?s=20 but don’t know if it’s genuine.
Apologies, £3-5 would be disappointing...
Nope, £2-3 would be disappointing, add a zero at the end Org/Aston.
Org, this is becoming tiresome.
@JoeyDiamond, great find and video (https://www.youtube.com/watch?v=ZYEJ1c4mD6Q) thanks.
@mact, worth listening to the panel discussion from 1hr 6 mins and you'll here them talking about inhaled interferon.
2 of 2:
"In particular,” says Wilfredo Garcia-Beltran, MD, PhD, a resident physician in the Department of Pathology at MGH and first author of the study, “we found that mutations in a specific part of the spike protein called the receptor binding domain were more likely to help the virus resist the neutralizing antibodies.” The three South African variants, which were the most resistant, all shared three mutations in the receptor binding domain. This may contribute to their high resistance to neutralizing antibodies.
Currently, all approved COVID-19 vaccines work by teaching the body to produce an immune response, including antibodies, against the SARS-CoV-2 spike protein. While the ability of these variants to resist neutralizing antibodies is concerning, it doesn’t mean the vaccines won’t be effective.
“The body has other methods of immune protection besides antibodies,” says Balazs. “Our findings don’t necessarily mean that vaccines won’t prevent COVID, only that the antibody portion of the immune response may have trouble recognizing some of these new variants.”
Like all viruses, SARS-CoV-2 is expected to continue to mutate as it spreads. Understanding which mutations are most likely to allow the virus to evade vaccine-derived immunity can help researchers develop next-generation vaccines that can provide protection against new variants. It can also help researchers develop more effective preventative methods, such as broadly protective vaccines that work against a wide variety of variants, regardless of which mutations develop."
Article highlighting why treatments like SNG001 are going to be needed despite vaccines, https://www.ragoninstitute.org/vaccine-induced-antibodies-may-be-less-effective-against-several-new-sars-cov-2-variants/
1 of 2:
"Researchers at the Ragon Institute of MGH, MIT and Harvard and at Massachusetts General Hospital find that neutralizing antibodies raised by COVID-19 vaccines are not as effective at neutralizing some new, circulating SARS-CoV-2 variants.
SARS-CoV-2, the virus that causes COVID-19, has mutated throughout the pandemic. New variants of the virus have arisen throughout the world, including variants that might possess increased ability to spread or evade the immune system. Such variants have been identified in California, Denmark, the U.K., South Africa and Brazil/Japan. Understanding how well the COVID-19 vaccines work against these variants is vital in the efforts to stop the global pandemic, and is the subject of new research from the Ragon Institute of MGH, MIT and Harvard and Massachusetts General Hospital.
In a study recently published in Cell, Ragon Core Member Alejandro Balazs, PhD, found that the neutralizing antibodies induced by the Pfizer and Moderna COVID-19 vaccines were significantly less effective against the variants first described in Brazil/Japan and South Africa. Balazs’s team used their experience measuring HIV neutralizing antibodies to create similar assays for COVID-19, comparing how well the antibodies worked against the original strain versus the new variants.
“We were able to leverage the unique high-throughput capacity that was already in place and apply it to SARS-CoV-2,” says Balazs, who is also an assistant professor of Medicine at Harvard Medical School and assistant investigator in the Department of Medicine at MGH. “When we tested these new strains against vaccine-induced neutralizing antibodies, we found that the three new strains first described in South Africa were 20-40 times more resistant to neutralization, and the two strains first described in Brazil and Japan were five to seven times more resistant, compared to the original SARS-CoV-2 virus.”
Neutralizing antibodies, explains Balazs, work by binding tightly to the virus and blocking it from entering cells, thus preventing infection. Like a key in a lock, this binding only happens when the antibody’s shape and the virus’s shape are perfectly matched to each other. If the shape of the virus changes where the antibody attaches to it – in this case, in SARS-CoV-2’s spike protein – then the antibody may no longer be able to recognize and neutralize the virus as well. The virus would then be described as resistant to neutralization.
..."
Interesting article that begins “ Stronger interferon production, greater T cell activation, and increased susceptibility to autoimmunity are just some of the ways that females seem to differ from males.”
https://www.the-scientist.com/features/sex-differences-in-immune-responses-to-viral-infection-68466
Cheers spred, you can see changes here, https://clinicaltrials.gov/ct2/history/NCT04732949?A=1&B=2&C=merged#StudyPageTop
Long way to go yet - if you have any doubts as to why SNG001 is on ACTIV-2, read this https://www.theguardian.com/us-news/2021/feb/22/us-coronavirus-death-toll-passes-500000
Please both give it a rest gents.
Wishing you no luck whatsoever with that happy.
@happyinvestor100, are you a shareholder in Synairgen?
Scinv, SNG001 is Synairgen’s proprietary formulation of inhaled interferon beta-1a - that’s what’s being trialled.